☰

Cheng-Yu Tsai, Ph.D. - Publications

Affiliations: 
2009 The University of Texas Graduate School of Biomedical Sciences at Houston 
Area:
Pharmacology
Tree Info Grants Similar researchers PubMed Report error

16 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Tsai C, Zhang H, Rice WG, Howell SB. Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations Blood. 134: 5755-5755. DOI: 10.1182/Blood-2019-123571  0.409
2019 Local A, Tsai C, Zhang H, Sheng S, Benbatoul K, Howell SB, Rice WG. Abstract 2096: Resistance to APTO-253 caused by internal deletion and alternate promoter usage of the MYC gene in malignant B cells Cancer Research. 79: 2096-2096. DOI: 10.1158/1538-7445.Sabcs18-2096  0.42
2018 Local A, Zhang H, Benbatoul KD, Folger P, Sheng X, Tsai CY, Howell SB, Rice WG. APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells. Molecular Cancer Therapeutics. 17: 1177-1186. PMID 29626127 DOI: 10.1158/1535-7163.Mct-17-1209  0.372
2018 Tsai CY, Sun S, Zhang H, Local A, Su Y, Gross LA, Rice WG, Howell SB. APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency. Molecular Cancer Therapeutics. 17: 1167-1176. PMID 29626126 DOI: 10.1158/1535-7163.Mct-17-0834  0.362
2018 Zhang H, Local A, Benbatoul K, Folger P, Sheng S, Tsai C, Howell SB, Rice WG. Abstract 794: CG'806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro Cancer Research. 78: 794-794. DOI: 10.1158/1538-7445.Am2018-794  0.399
2018 Champa D, Sun S, Tsai C, Howell S, Harismendy O. Abstract 2860A: Evolution and characterization of carboplatin resistance at single-cell resolution Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-2860A  0.326
2017 Zhang H, Local A, Benbatoul K, Folger P, Sheng S, Tsai C, Howell S, Rice W. CG '806, a First-in-Class Non-Covalent Pan-FLT3/BTK Inhibitor, Exerts Superior Potency Against B-Cell Malignant Cells Blood. 130: 5200-5200. DOI: 10.1182/Blood.V130.Suppl_1.5200.5200  0.366
2017 Local A, Zhang H, Benbatoul K, Folger P, Sheng S, Tsai C, Howell S, Rice W. APTO-253 Interaction with G-Quadruplex DNA Is Linked to Inhibition of c-Myc Expression, Induction of DNA Damage, and Generation of Synthetic Lethality in Cells with BRCA1/2 Impairment Blood. 130: 5094-5094. DOI: 10.1182/Blood.V130.Suppl_1.5094.5094  0.38
2017 Zhang H, Local A, Benbatoul K, Folger P, Sheng S, Tsai C, Howell S, Rice W. CG '806, a Highly Potent First-in-Class Pan-FLT3/BTK Inhibitor, Targets Multiple Clusters of Kinases Operative in Diverse Subtypes of Acute Myeloid Leukemia Blood. 130: 5063-5063. DOI: 10.1182/Blood.V130.Suppl_1.5063.5063  0.361
2016 Bompiani KM, Tsai CY, Achatz FP, Liebig JK, Howell SB. Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity. Metallomics : Integrated Biometal Science. 8: 951-62. PMID 27157188 DOI: 10.1039/C6Mt00076B  0.344
2016 Tsai C, Zhang H, Local A, Rice WG, Howell SB. Mechanisms of Resistance to Apto-253 Blood. 128: 5247-5247. DOI: 10.1182/Blood.V128.22.5247.5247  0.355
2015 Tsai CY, Liebig JK, Tsigelny IF, Howell SB. The copper transporter 1 (CTR1) is required to maintain the stability of copper transporter 2 (CTR2). Metallomics : Integrated Biometal Science. 7: 1477-87. PMID 26205368 DOI: 10.1039/C5Mt00131E  0.356
2014 Tsai CY, Larson CA, Safaei R, Howell SB. Molecular modulation of the copper and cisplatin transport function of CTR1 and its interaction with IRS-4. Biochemical Pharmacology. 90: 379-87. PMID 24967972 DOI: 10.1016/J.Bcp.2014.06.019  0.335
2012 Tsai CY, Finley JC, Ali SS, Patel HH, Howell SB. Copper influx transporter 1 is required for FGF, PDGF and EGF-induced MAPK signaling. Biochemical Pharmacology. 84: 1007-13. PMID 22842628 DOI: 10.1016/J.Bcp.2012.07.014  0.338
2010 Tsai WW, Wang Z, Yiu TT, Akdemir KC, Xia W, Winter S, Tsai CY, Shi X, Schwarzer D, Plunkett W, Aronow B, Gozani O, Fischle W, Hung MC, Patel DJ, et al. TRIM24 links a non-canonical histone signature to breast cancer. Nature. 468: 927-32. PMID 21164480 DOI: 10.1038/Nature09542  0.388
2009 Tsai CY, Ray AS, Tumas DB, Keating MJ, Reiser H, Plunkett W. Targeting DNA repair in chronic lymphocytic leukemia cells with a novel acyclic nucleotide analogue, GS-9219. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3760-9. PMID 19435836 DOI: 10.1158/1078-0432.Ccr-08-2848  0.438
Show low-probability matches.